Open AccessSolvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer
Author(s) -
Keiji Sugiyama,
Yoshihito Kogure,
Atsushi Torii,
Kazuhiro Shiraishi,
Ayaka Yamada,
Akane Ishida,
Fumie Shigematsu,
Kazuki Nozawa,
Hideyuki Niwa,
Saori Oka,
Masashi Nakahata,
Chiyoe Kitagawa,
Masahide Oki,
Hideo Sasaki
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000014758
Subject(s) - medicine , neutropenia , clinical endpoint , paclitaxel , lung cancer , refractory (planetary science) , adverse effect , toxicity , febrile neutropenia , oncology , retrospective cohort study , gastroenterology , surgery , chemotherapy , clinical trial , physics , astrobiology
Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily treated patients should be assessed. Here, we evaluated the efficacy of paclitaxel (PTX) in R/R SCLC patients. A single-institute retrospective chart review was conducted. The primary endpoint was overall survival (OS), whereas the secondary endpoints were progression-free survival (PFS), overall response rate, disease control rate (DCR), and safety. Thirty-one patients (median age, 69 [range, 56–80] years) were analyzed. The median follow-up period was 122 (range, 28–1121) days. The median OS and PFS were 4.4 and 2.2 months, respectively. Adverse events of grade 3 or higher, other than hematological toxicity, were febrile neutropenia and neuropathy. Multivariate analyses identified the following independent predictors of poor OS: performance status and lactate dehydrogenase at the upper limit of normal. PTX monotherapy showed moderate efficacy with acceptable toxicity in heavily treated patients with R/R SCLC patients.